About Us

The cornerstone of Cell>Point is metabolic imaging and therapeutic targeting through intranuclear chelation technology. The company is developing universal oncology, cardiology, stroke and diabetes molecular imaging agents, and intranuclear metallic therapeutics. Cell>Point is a privately held biotechnology company headquartered in Centennial, Colorado. The company's five technology platforms, ethylenedicysteine drug conjugate technology (“EC Technology”), In-Situ Hydrogel (“In Situ Hydrogel Technology”), tetraazacyclopentadecane technology (“N₄ Technology”), oligosaccharide conjugate technology (“Dual Agent Technology”) and mechanism-based targeted pancreatic beta cell technology (“Beta Cell Technology”) are being developed to create new radiodiagnostic imaging agents, new intranuclear therapeutic agents, and high yield delivery systems for the administration of local regional radio/chemotherapy. In radiodiagnostic imaging, the company is developing agents for single photon emission computed tomography (“SPECT”) cameras, positron emission tomography (“PET”) cameras and dual agents for SPECT or PET cameras in combination with either computed tomography (“CT”) cameras or magnetic resonance imaging (“MRI”) cameras.

EC Technology

Cell>Point’s proprietary derivation of ethylenedicysteine (EC) is being used as an exceptionally stable functional chelate that provides significant versatility to facilitate the development of cellular-targeted analogues for applications in diagnostic imaging, cold metallic therapy and radiotherapy. Cell>Point is currently sponsoring Phase II/III clinical trials for its first ^99mTc labeled sugar analogue, ^99mTc-EC-Glucosamine (^99mTc-EC-G), for radiodiagnostic imaging in oncology. The multicenter clinical trial is comparing ^99mTc-EC-G /SPECT imaging with FDG-PET imaging for assessing and staging patients with (non-small cell) lung cancer. The sites for the clinical trial include Johns Hopkins, Mayo Clinic, Montefiore Medical Center, Miami Baptist, Decatur Memorial Hospital, the University of Chicago, and British Columbia Medical Center (Canada). Following non-small cell lung cancer, the company plans to sponsor Phase IV clinical trials to evaluate ^99mTc-EC-G in lymphoma, non-Hodgkin’s lymphoma, breast, colon, liver, head and neck, colorectal, and prostate cancer. Recent canine studies conducted at the University of Virginia indicate that ^99mTc-EC-G may have application as a functional imaging agent for assessing myocardial ischemia, myocardial viability, cardiotoxicity, and congestive heart failure. The company is preparing to file a cardiology IND with the FDA during the 1^st Quarter 2010 for authorization to commence a Phase II/III clinical trial study. In addition to labeling EC-G with ^99mTc for SPECT imaging, EC-G can also be labeled with ⁶⁸Ga for PET imaging. ⁶⁸Ga is a generator produced medical isotope and it is the company’s understanding that the first pharmaceutical grade gallium generator should be approved for commercial availability by the 4th quarter 2010 or early 2011. On the therapy side, EC-G is the backbone for the company’s first intranuclear cold metallic therapeutic, ¹⁸⁷Re-EC-G, which is currently in preclinical studies. The company plans to clinically study the therapeutic use of ¹⁸⁷Re-EC-G in patients with lymphoma beginning late 2010 or early 2011. ¹⁸⁷Re-EC-G functions similar to a chemotherapeutic drug except that ¹⁸⁷Re-EC-G will be a targeted therapy. Following ¹⁸⁷Re-EC-G will be ¹⁸⁸Re-EC-G, which will be an intranuclear radiotherapeutic agent. On the diagnostic side, ^99mTc-EC-Metronidazole, a hypoxia imaging agent, will follow ^99mTc-EC-G. The company believes that this product may prove clinically useful in providing critical information to the physician whether a patient has suffered an ischemic or hemorrhagic stroke. By the end of 2009, the GMP synthesis of the compound should be complete.

Cell>Point believes that ^99mTc-EC-G will have the capacity to assess pharmacological response and biochemical process thus providing staging, grading, treatment follow-up and assistance in the selection of patients who should be more responsive to the particular treatment being considered. The versatility of EC Technology has been demonstrated in (i) receptor targeting (EGF, ER, AR, HER 2, LH, somatostatin, transferrin, etc.), (ii) transcriptional targeting (glucosamine, deoxyglucose, doxorubicin, etc.), (iii) tissue hypoxia targeting (metronidazole), (iv) apoptosis targeting (annexin V), (v) vascular targeting (e.g. angiostatin, interferon alpha, colchicine, paclitaxel, etc.), (vi) gene expression targeting (penciclovir, 5-flurocytidine) and (vii) enzymatic targeting (cox-2, mmp-2 and mmp-9).

Beta Cell Technology

The diagnostic objective of the Beta Cell technology platform is to target beta cell function in the pancreas. The first diagnostic agent developed from the Beta Cell platform is ^99mTc-DTPA-Glipizide. The GMP synthesis of the compound has been completed and a preclinical small animal study is underway at the University of Chicago using ^99mTc-DTPA-Glipizide to evaluate the therapeutic efficacy of diabetic drugs through pancreatic beta cell activity. In addition, ^99mTc-DTPA- Glipizide will be evaluated in its ability to distinguish and evaluate Type I and Type II diabetes and to identify the presence of early stage pancreatic cancer.

In Situ Hydrogel

The third technology platform, In-Situ Hydrogel, is being developed as a site specific regional chemotherapy and radiotherapy delivery system. By comparison with other hydrogel technologies, In-Situ Hydrogel is unique in that it is capable of delivering a high yield dose of a therapeutic radionuclide, such as rhenium-188 (“¹⁸⁸Re”), directly to the tumor site without collateral leakage into surrounding healthy tissue. In addition, In-Situ Hydrogel is capable of simultaneously delivering a therapeutic radionuclide and a chemotoxic drug to treat solid tumors and surgically unresectable tumors. The absence of post injection leakage should help reduce the side-effects experienced by patients who receive external beam radiation treatment. Pre-clinical studies have demonstrated the potential of In-Situ Hydrogel as an effective high yield delivery system. The hydrogel formulation traps the radionuclide and/or chemotherapeutic drug at the tumor site immediately following administration. The radionuclide remains trapped within the polysaccharide matrix while the chemotherapeutic drug slowly releases.

N₄ Technology

The fourth technology platform, N₄ Technology, is a covalent lipophilic technology that is being used to develop agents for the treatment of Alzheimer's, Parkinson’s, Huntington’s disease, depression and neuroendocrine tumors.

Dual Agent Technology

The fifth technology platform, Dual Agent Technology, is facilitating the development of dual use diagnostic agents. For example, a single agent will combine the radiopharmaceutical for SPECT imaging with the contrast marker for MRI or CT without interference or distortion between the radiopharmaceutical and contrast marker. The company plans to develop dual agents for use with SPECT/CT, SPECT/MRI, PET/CT and PET/MRI combination cameras. In addition, Dual Agent Technology will be used to develop special imaging agents for optical imaging and targeted radio/chemotherapeutic compounds.